Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01561690 · ClinicalTrials.gov registry record · Phase 2

A Study of ARRY-502 in Patients With Persistent Asthma

A Phase 2 study of Asthma, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
184
Enrollment target
20
Study locations

NCT01561690 is a Phase 2 study of Asthma that has completed, run by Pfizer. The registered enrollment target is 184 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01561690, a Phase 2 study of Asthma, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
184 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this study.

Conditions Studied

Asthma

Interventions

  • DRUG Placebo; oral
  • DRUG ARRY-502, CRTh2 antagonist; oral

Study Locations (20)

California

  • Allergy & Asthma Specialists Medical Group - Huntington Beach
  • Allergy Medical Clinic - Research Division - Los Angeles
  • California Allergy & Asthma Med. Group - Los Angeles
  • Southern California Institute for Respiratory Diseases Inc - Los Angeles
  • Southern California Research - Mission Viejo
  • Peninsula Research Associates - Rolling Hills Estates
  • Allergy Associates Medical Group - San Diego

Florida

  • Clinical Neuroscience Solutions - Jacksonville
  • Pulmonary Disease Specialists - Kissimmee
  • South Florida Research Trials - Miami
  • Allergy & Asthma Diagnostic Treatment Center - Tallahassee
  • Florida Pulmonary Research Institute - Winter Park

Colorado

  • Colorado Allergy and Asthma Center - Centennial
  • IMMUNOe International Research Centers - Centennial
  • Asthma & Allergy Associates PC - Colorado Springs
  • Rocky Mountain Center for Clinical Research - Wheat Ridge

Idaho

  • Idaho Research - Eagle

Illinois

  • Sneeze, Wheeze & Itch - Normal

Maryland

  • Chesapeake Clinical Research Inc - Baltimore

Massachusetts

  • Northeast Medical Research Associates - North Dartmouth

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2012-04-02
Est. Completion 2013-06-10
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01561690

The ClinicalTrials.gov registry entry for NCT01561690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (88% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo; oral is the first listed.

NCT01561690 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT01561690 about?

NCT01561690 is a clinical study titled "A Study of ARRY-502 in Patients With Persistent Asthma". This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this ...

What is the current status of trial NCT01561690?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2012-04-02. Estimated completion is 2013-06-10.

What conditions does trial NCT01561690 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT01561690?

The interventions under investigation include: Placebo; oral (DRUG), ARRY-502, CRTh2 antagonist; oral (DRUG).

Who is sponsoring clinical trial NCT01561690?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01561690 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.